News

IMI launches seven projects
Enlarge image

FundingEUFranceUK

IMI launches seven projects

11.06.2012 - The Innovative Medicines Initiative (IMI) has announced details on seven projects funded with a total budget of €215m.

The projects funded within the next five years include two coordinated by GlaxoSmithKline plc: model-based preclinical development of anti-tuberculosis (TB) drug combinations (PreDiCT-TB), which aim to make tuberculosis treatments more patient-friendly; and development of tools to predict immune response to biopharmaceuticals (ABIRISK). Sanofi is coordinating the DIRECT project to research patient stratification for personalised Type II diabetes treatments. Novartis AG and The University of Surrey (UK) are working on a project to develop biomarkers to test the safety of vaccines (BIOVACSAFE). A project coordinated by AstraZeneca plc is to develop tests for drug-induced liver injury (MIP-DILI); and one consortium coordinated by Roche seeks to develop research tools and diagnostics for autism spectrum disorder (EU-AIMS). 

IMI also announced the launch of a Education and Training project called EUPATI, which shall create a European Patients’ Academy on Therapeutic Innovation. Its aim is to educate patients and the public about medicines development and empower patients to engage more effectively in the drug development process. The new projects mean that IMI is now supporting a total of 30 projects with a combined total cost of over €650m. IMI is a public-private partnership in health research and development. The European Union contributes €1 bn to the IMI research programme, which is matched by contributions worth at least another €1bn from the member companies of the European Federation of Pharmaceutical Industries and Associations (EFPIA).

http://www.european-biotechnology-news.com/news/news/2012-02/imi-launches-seven-projects.html

FinancingBelgium

20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.

Stock marketsFranceEU

19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.

ResearchUK

18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.

M&AUKSwitzerland

13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.

R&DAustriaFrance

12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.

M&AFranceEU

07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.

Prenatal DiagnosticsEUUK

06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.

GenericsSpainGermanyEU

04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.

Drug discoveryUKSwitzerland

30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.

Nuclear medicineNorwayFrance

28.06.2016 Nordic Nanovector has teamed up with Areva Med to develop a treatment for leukaemia. The compound in question is a lead-212 conjugated anti-CD37 antibody.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN (D)1.50 EUR12.78%
  • BIOCARTIS GROUP NV (B)7.57 EUR7.53%
  • SWEDISH ORPHAN BIOVITRUM (S)13.11 USD6.59%

FLOP

  • NICOX (F)11.57 EUR-8.61%
  • KAROLINSKA (S)7.55 SEK-4.43%
  • AB SCIENCE (F)14.20 EUR-4.05%

TOP

  • PROTHENA PLC (IE)53.17 USD49.9%
  • FLAMEL TECHNOLOGIES (F)12.49 USD32.2%
  • TIGENIX (B)1.05 EUR26.5%

FLOP

  • MOLOGEN (D)1.50 EUR-40.0%
  • EVOCUTIS (UK)0.04 GBP-20.0%
  • SANTHERA (CH)56.75 CHF-18.9%

TOP

  • KARO BIO (S)28.70 SEK1705.0%
  • NICOX (F)11.57 EUR493.3%
  • SAREUM HOLDINGS (UK)0.64 GBP166.7%

FLOP

  • BB BIOTECH (D)45.22 EUR-84.5%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.64 SEK-79.3%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 25.07.2016